ProKidney Corp. (PROK)

ProKidney director Brian Pereira sold 757,164 shares of Class A Common Stock for approximately $1.07 million between August 18 and August 20, 2026. The sales were made at prices ranging from $1.3712 to $1.4407 per share, leaving him with zero beneficial ownership. Meanwhile, ProKidney also announced the appointment of Kenneth Locke as Chief Technical Officer to strengthen its leadership and support clinical development.

ProKidney Director Brian JG Pereira sold his entire holding of Class A Common Stock over three consecutive trading days, from August 18 to August 20, 2026. These transactions, both direct and indirect through a trust, were open-market sales. Following these sales, Pereira holds no shares in ProKidney Corp.

ProKidney Corp. (PROK) director Brian J. G. Pereira reported selling a total of 757,164 shares of Class A Common Stock between August 18–20, 2026. The sales included both direct holdings and shares held indirectly by the Brian J. G. Pereira 2012 Irrevocable Trust, at weighted average prices ranging from $1.345 to $1.50 per share. These transactions, reported via a Form 4 filing, indicate a high-impact and negative sentiment for the company from an insider trading perspective.

Morgan Stanley and its affiliate, Morgan Stanley Investment Management Inc., have reported their current beneficial ownership in ProKidney Corp. Class A common stock through a Schedule 13G/A amendment. Both entities now hold a 4.7% stake, individually owning approximately 9.65 million and 9.64 million shares respectively, all through shared voting and dispositive power. Crucially, both Morgan Stanley entities have ceased to be beneficial owners of more than five percent of ProKidney's Class A common stock.

ProKidney Corp. reported a net loss of $89.1 million for the first half of 2026 and flagged substantial doubt about its ability to continue as a going concern, as its current cash and marketable securities of $181.6 million are not expected to fund operations for 12 months after the August 10, 2026 filing date without additional financing. The biotech company, which is developing rilparencel for advanced diabetic CKD, saw its operating expenses rise to $93.7 million, primarily due to increased R&D for its Phase 3 PROACT 1 study. Despite achieving a positive Phase 3 enrollment milestone and receiving FDA's RMAT designation for rilparencel, the company faces significant liquidity challenges and an accumulated deficit of $1.32 billion.